HR for Mortality from Stroke For Log UTXB by ASA Group

The PHREG Procedure

Aspirin Use=No Aspirin Use

Model Information	
Data Set	WORK.SURVIVALSTROKE
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1681
Number of Observations Used	1375

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1375	7	1368	99.49

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	98.874	98.830
AIC	98.874	100.830
SBC	98.874	100.776

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	0.0444	1	0.8332
Score	0.0439	1	0.8341
Wald	0.0439	1	0.8340

Analysis of Maximum Likelihood Estimates						
Parameter	DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio
logtxb	1	0.10413	0.49700	0.0439	0.8340	1.110

HR for Mortality from Stroke For Log UTXB by ASA Group

The PHREG Procedure

Aspirin Use=No Aspirin Use

Hazard Ratios for logtxb			
Description	**Point Estimate**	**95% Wald Confidence Limits**	
logtxb Unit=1	1.110	0.419	2.939

HR for Mortality from Stroke For Log UTXB by ASA Group

The PHREG Procedure

Aspirin Use=Aspirin Use

Model Information	
Data Set	WORK.SURVIVALSTROKE
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1363
Number of Observations Used	996

Summary of the Number of Event and Censored Values			
Total	**Event**	**Censored**	**Percent Censored**
996	22	974	97.79

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	**Without Covariates**	**With Covariates**
-2 LOG L	296.625	295.358
AIC	296.625	297.358
SBC	296.625	298.449

Testing Global Null Hypothesis: BETA=0			
Test	**Chi-Square**	**DF**	**Pr > ChiSq**
Likelihood Ratio	1.2670	1	0.2603
Score	1.3824	1	0.2397
Wald	1.3833	1	0.2395

Analysis of Maximum Likelihood Estimates						
Parameter	**DF**	**Parameter Estimate**	**Standard Error**	**Chi-Square**	**Pr > ChiSq**	**Hazard Ratio**
logtxb	1	0.36615	0.31131	1.3833	0.2395	1.442

HR for Mortality from Stroke For Log UTXB by ASA Group

The PHREG Procedure

Aspirin Use=Aspirin Use

Hazard Ratios for logtxb			
Description	**Point Estimate**	**95% Wald Confidence Limits**	
logtxb Unit=1	1.442	0.783	2.655

The PHREG Procedure

Model Information	
Data Set	WORK.SURVIVALSTROKE
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	3044
Number of Observations Used	2371

Class Level Information		
Class	**Value**	**Design Variables**
q2u	**Q4**	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	**Event**	**Censored**	**Percent Censored**
2371	29	2342	98.78

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	**Without Covariates**	**With Covariates**
-2 LOG L	441.214	441.059
AIC	441.214	443.059
SBC	441.214	444.426

Testing Global Null Hypothesis: BETA=0			
Test	**Chi-Square**	**DF**	**Pr > ChiSq**
Likelihood Ratio	0.1557	1	0.6931
Score	0.1609	1	0.6883
Wald	0.1606	1	0.6886

The PHREG Procedure

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
q2u	1	0.1606	0.6886

Analysis of Maximum Likelihood Estimates								
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
q2u	Q4	1	0.17391	0.43398	0.1606	0.6886	1.190	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3		
Description	Point Estimate	95% Wald Confidence Limits
q2u Q4 vs Q1-Q3	1.190	0.508 2.786

The PHREG Procedure

Aspirin Use=No Aspirin Use

Model Information	
Data Set	WORK.SURVIVALSTROKE
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1681
Number of Observations Used	1375

Class Level Information		
Class	**Value**	**Design Variables**
q2u	**Q4**	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	**Event**	**Censored**	**Percent Censored**
1375	7	1368	99.49

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	**Without Covariates**	**With Covariates**
-2 LOG L	98.874	98.661
AIC	98.874	100.661
SBC	98.874	100.607

Testing Global Null Hypothesis: BETA=0			
Test	**Chi-Square**	**DF**	**Pr > ChiSq**
Likelihood Ratio	0.2136	1	0.6440
Score	0.2301	1	0.6315
Wald	0.2276	1	0.6333

The PHREG Procedure

Aspirin Use=No Aspirin Use

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
q2u	1	0.2276	0.6333

Analysis of Maximum Likelihood Estimates								
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
q2u	Q4	1	0.39918	0.83681	0.2276	0.6333	1.491	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3		
Description	Point Estimate	95% Wald Confidence Limits
q2u Q4 vs Q1-Q3	1.491	0.289 7.685

The PHREG Procedure

Aspirin Use=Aspirin Use

Model Information	
Data Set	WORK.SURVIVALSTROKE
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1363
Number of Observations Used	996

Class Level Information		
Class	**Value**	**Design Variables**
q2u	**Q4**	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	**Event**	**Censored**	**Percent Censored**
996	22	974	97.79

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	**Without Covariates**	**With Covariates**
-2 LOG L	296.625	296.578
AIC	296.625	298.578
SBC	296.625	299.669

Testing Global Null Hypothesis: BETA=0			
Test	**Chi-Square**	**DF**	**Pr > ChiSq**
Likelihood Ratio	0.0469	1	0.8285
Score	0.0480	1	0.8266
Wald	0.0479	1	0.8267

The PHREG Procedure

Aspirin Use=Aspirin Use

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
q2u	1	0.0479	0.8267

Analysis of Maximum Likelihood Estimates							
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
q2u	Q4	1	0.11139	0.50885	0.0479	0.8267	1.118	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3		
Description	Point Estimate	95% Wald Confidence Limits
q2u Q4 vs Q1-Q3	1.118	0.412	3.030